Introduction
Prostate cancer is the most common type of cancer diagnosed in American men and is the second leading cause of cancer-related death in men (Pienta and Loberg, 2005) . American Cancer Society estimates about 28 660 men will die of this disease in 2008. Most men diagnosed with prostate cancer can survive the primary localized tumor, but because of the metastasisrelated disease, mortality rates remain extremely high. Metastasis of prostate cancer is facilitated by migration and invasion of malignant tumor cells from localized neoplastic tumors to distant organs like bone by cleavage of extracellular matrix (ECM) (Arya et al., 2006) . Proteases that facilitate malignant cell migration and invasion by cleaving ECM proteins, such as matrix metalloproteinases (MMPs), cysteine proteases and serine proteases have been extensively studied (Sliva, 2004) . Although the fundamental function of these proteases in prostate cancer cell migration, invasion and metastasis is clear, the underlying mechanism and regulation of these proteases to promote prostate cancer progression and invasion is vague.
Chromosome 17q12 contains multiple genes that are important in different forms of cancer. Recent genetic studies have projected 17q12 loci genes as an important risk factor in prostate cancer progression in selected individuals (Eeles et al., 2008; Sun et al., 2008) . ERBB2 located in the same amplicon is known to have significant function in prostate cancer progression and its expression correlates with poor hormone refractory prostate cancer in patients (Myers et al., 1994) . C17orf37 is a novel gene located in the same amplicon next to ERBB2 in a tail-to-tail rearrangement, functional importance of which is presently unknown. C17orf37 has been reported to be frequently amplified with ERBB2 in breast tumor cells, however independent activation of C17orf37 has been demonstrated in cell lines expressing low levels of ERBB2 (Evans et al., 2006) . C17orf37 protein is abundantly expressed in breast tumor cells and clinical tissues, with reduced or limited expression in 38 different normal tissues (Evans et al., 2006) . C17orf37 expression positively correlates with grade and stage of breast cancer, and increased expression has been shown in patients with breast to liver and lungs metastasis (Evans et al., 2006) . This suggests C17orf37 protein may be an important mediator of cancer cell metastasis. However, to establish C17orf37 as a biomarker and therapeutic target for cancer treatment, it is utmost important to explore the functional importance of this novel protein.
We demonstrate C17orf37 expression is enhanced in prostate cancer cells and tissues specimens. We also observed the cellular localization of C17orf37 in prostate cells by confocal microscopy and finally by knockdown and overexpression studies, we demonstrate C17orf37 significantly contributes to the migration and invasion of prostate cancer cells. Our results clearly indicate C17orf37 as a critical cancer-specific protein promoting tumor cell invasion by enhancing secretion of urokinase plasminogen activator (uPA), MMP-9 and vascular endothelial growth factor (VEGF) through nuclear factor-kB (NF-kB) pathway.
Results

Increased expression of C17orf37 in prostate cancer cells
To investigate C17orf37 expression in prostate cancer, we analysed mRNA expression of C17orf37 in a panel of prostate cancer cell lines including androgen-independent DU-145 and PC-3, and in an LNCaP cell line prostate cancer progression model consisting of androgen-dependent LNCaP-R and androgen-independent LNCaP-UR (Rothermund et al., 2002) by q-RT-PCR ( Figure 1a ) and reverse transcription (RT)-PCR (Supplementary Figure 1 ). We found high levels of C17orf37 mRNA expression in all the prostate cancer cell lines investigated, whereas expression in both the normal prostate epithelial cell lines HPV18 C-1 and PWR-1E was relatively low (Figure 1a) . To analyse the protein expression of C17orf37 in prostate carcinoma cells, we first determined the specificity of the anti-C17orf37 antibody (ORF37) using recombinant GST-C17orf37 protein. ORF37 antibody immunoreacts with both GST-C17orf37 (39 kDa) and GST-tag cleaved purified recombinant C17orf37 protein of 12 kDa size ( Figure 1b) . To verify the 12 kDa band is indeed C17orf37 protein, we analysed the protein sequence by tandem mass spectrometry. As shown by high-resolution ESI-FTICR analysis (Supplementary Figure 2) , the molecular weight of the intact recombinant protein was 11 918 Da and matched 54% amino-acid sequence coverage of C17orf37 (Figure 1c) .
To find any possible change in C17orf37 protein expression from androgen dependency to independency, we examined two additional prostate cancer cell lines LNCaP-RF, a fast growing androgen-responsive LNCaP cell line (Rothermund et al., 2002) and LNCaP/C4-2 (LNC4-2), a subline derived from parental LNCaP cells that acquired phenotypes of androgen independence (Thalmann et al., 1994; Wu et al., 1994) . Among metastatic prostate cancer cell lines, DU-145 showed higher C17orf37 expression compared to PC-3 (Figure 1d ), whereas in vitro LNCaP prostate cancer progression models-UR, RF and R along with LNCaP C4-2-showed similar level of protein expression (Figure 1d ), suggesting C17orf37 expression persists both in androgen-dependent and -independent states of prostate cancer. As with our observations made at the mRNA level, normal prostate epithelial cell lines HPV18 C-1 and PWR-1E showed undetectable expression of C17orf37 protein (Figure 1d ). These data indicated that expression of C17orf37 persists throughout prostate cancer disease progression, both in early stages of androgen dependency to late stages of androgen independency, with minimal expression in normal prostate cell lines.
C17orf37 is overexpressed in high-grade neoplastic glands and stroma of prostate adenocarcinoma To determine the expression of C17orf37 in normal and cancerous prostate tissues, we examined C17orf37 expression in archival formalin-fixed paraffin-embedded prostate specimens by immunohistochemistry. The hematoxylin and eosin (H&E)-stained specimens were classified into normal, benign prostatic hyperplasia (BPH), moderately differentiated prostate adenocarcinoma and poorly differentiated prostate adenocarcinoma (Banerjee et al., 2003; Figures 2a and d) by anatomic pathologists. Gleason scores of the prostate carcinoma tissues ranged from 6 to 10, thus no well-differentiated prostate adenocarcinoma specimens (Gleason score 2-4) were available for our study. In both normal prostate glands (Figure 2b , left) and transurethral resection of the prostate BPH specimens (Figure 2b , middle), C17orf37 staining was minimal in prostatic glands and stroma. Prostate intraepithelial neoplasm (PIN) showed moderately increased staining of C17orf37 (Figure 2c ) compared to normal or BPH glands in the same section. However, in moderately differentiated specimens C17orf37 expression was found to be intense in the neoplastic glands and stromal cells surrounding the glands (Figure 2e , left). Strong C17orf37 expression was found throughout the poorly differentiated prostate cancer sections with intense diffused stain in the stroma around the malignant cell mass and invasive edges (Figure 2e , middle). C17orf37 expression was intense in the fused prostatic glands of poorly differentiated prostatic cancer (Figure 2e , 'inset' middle). The isotype controls (IgG) for each specimen did not show immunoreactivity (Figures 2b and e, right) . Taken together, immunohistochemical detection of C17orf37 protein showed prevalent expression in the higher grades of prostate adenocarcinoma with densely stained malignant cells compared to either low or null expression in both normal and BPH specimens. (Figures 3b and c) . Localization was similar in both C17orf37-positive prostate cancer cells DU-145 and LNCaP, and a null C17orf37 HPV18 C-1 (Figure 3c ). To determine whether C17orf37 is a membrane-bound protein, we performed total internal reflection fluores- (c) Summary of LC/ESI-MS/MS analysis for the predicted C17orf37 after tryptic digestion (4 unique peptides and 54% sequence coverage, 62 out of 115 amino-acid residues shown; the box indicates the amino-acid residues covered and gray highlight denotes conversion of E to oE upon proteolytic digestion). (d) C17orf37 protein was analysed by western immunoblot in a panel of prostate cancer cell lines including DU-145, PC-3 and LNC4-2 (androgen independent); LNCaP progression model LNCaP-UR, LNCaP-RF and LNCaP-R (from androgen independent to dependent); and, normal prostate epithelial cell line HPV18 C-1 and PWR-1E. Housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading control. Expression of C17orf37 protein was higher in prostate cancer cells compared to normal prostate cells. Figure 3d ). We used intracellular cytoskeletal protein tubulin as a control for our experiments, but TIRFM failed to image tubulin protein molecules on the membrane (Figure 3d , right). These results indicated that C17orf37 is a cytosolic protein with predominant membrane localization in prostate cancer cells.
Expression of C17orf37 enhances the in vitro invasive and migratory potential of prostate cancer cells
Our results show expression of C17orf37 is higher in advanced prostate adenocarcinomas (Gleason grades: 6 and 9) compared to normal prostate tissues (Figures 2b and e). Metastases of malignant cells to distant tissues or organs are mediated by cellular migration, invasion and proteolytic activity that degrade tissue barrier (Sliva, 2004) . To investigate the function of C17orf37 in prostate cancer cell migration, we studied the effect of C17orf37 downregulation on the migratory potential of DU-145 cells. Using gene-specific siRNA at varying concentrations, we blocked the endogenous expression of C17orf37 in DU-145 cells ( Figure 4a ). An in vitro agarose gel bead assay was performed with C17orf37 knocked-down DU-145 cells, to determine the dosedependent effect of siRNA-C17orf37 on DU-145 cell migration. As shown in Figure 4b , siRNA-C17orf37 treatment ( Figure 4b , III-V) reduced the number of DU-145 cells that could migrate out of the agarose gel bead into the medium compared to wild-type or controlsiRNA-treated (Figure 4b , I-II) cells. siRNA-C17orf37 treatment at 100 nM resulted in B10-fold decrease in migration of DU-145 cells (Po0.0001) compared to control wild-type cells (Figure 4c ). In vitro tumor invasion assay also showed reduced invasive ability of ) and serine proteases (such as uPA) that degrade the ECM (Sliva, 2004) . During prostate cancer progression these molecules are found to be predominantly upregulated to facilitate migration and invasion (Wilson and Sinha, 1993; Lokeshwar, 1999; Wilson et al., 2004; Helenius et al., 2006; Li and Cozzi, 2007) . Prostate cancer cells also secrete high levels of growth factors like VEGF, which is an important mediator of angiogenesis, proliferation and migration (Hicklin and Ellis, 2005) .
To investigate whether C17orf37 protein has any effect on the metastasis-related genes, we knocked down endogenous C17orf37 in DU-145 cells and analysed expression of several genes that facilitate prostate cancer metastasis and promote ECM cleavage. We observed suppression of endogenous C17orf37, simultaneously reduced MMP-9, uPA and VEGF expression as measured by RT-PCR ( Figure 5a ) and western immunoblot ( Figure 5b ) compared to nontargeting siRNA (control siRNA). To determine if C17orf37 expression increases MMP-9, uPA and VEGF protein in prostate cancer cells, we overexpressed C17orf37 in DU-145 cells by transient transfection of GFP-C17orf37 plasmid. As shown in Figure 5c , western immunoblot confirmed overexpression of C17orf37 increases endogenous MMP-9, uPA and VEGF protein compared to vector-treated cells. Interestingly, silencing of C17orf37 in DU-145 prostate cancer cells resulted in reduced mRNA expression of both the isoforms of VEGF (VEGF 165 and VEGF 121 ; Figure 5a ). VEGF 121 isoform is rapidly secreted and freely diffuses into the tissues, whereas VEGF 165 the potent isoform functionally active in most angiogenic states (Connolly and Rose, 1998; Woolard et al., 2004 ) was found to be regulated by C17orf37 (Figures 5b and c) . To quantitate the relative amount of secreted VEGF (both the isoforms) and MMP-9 we performed enzyme-linked immunosorbent assay (ELISA) of conditioned media from DU-145 cells overexpressed or depleted C17orf37 protein. Our results show that secreted MMP-9 and VEGF protein are significantly altered due to C17orf37 expression compared to respective controls (Figure 5d ). MMP-9, uPA and VEGF genes are transcriptionally upregulated by NF-kB, which is constitutively active in prostate cancer cells (Suh and Rabson, 2004) . We performed electrophoretic mobility shift assay (EMSA) to evaluate the DNA-binding activity of NF-kB in C17orf37-silenced DU-145 cells. Our results indicate increasing concentration of C17orf37-specific siRNA effectively inhibited NF-kB DNA-binding activity in a dose-dependent manner (Figure 6a ). These results show that C17orf37 increases migration and invasion in prostate cancer by NF-kB-mediated genes MMP-9, uPA and VEGF. In prostate cancer cells, constitutive activation of NF-kB is mediated by upstream protein kinase B (PKB/Akt) (Fresno Vara et al., 2004) , so we performed western immunoblot to detect the levels of phosphorylated Akt (p-Akt) and total Akt. p-Akt is the active form of the protein that cascades the intracellular signaling and our results show blocking of C17orf37 by siRNA dramatically reduced p-Akt level in DU-145 cells (Figure 6b ). C17orf37-specific siRNA (100 nM) treatment abolished 80% phosphorylation of Akt in DU-145 cells (Supplementary Figure 4) whereas the total Akt expression was constant when normalized to loading control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We also observed reduction in the phosphorylated form of ERK1/2 compared to total ERK1/2 (Figure 6b ), however the extent of reduction was not significant when compared to Akt activation (Supplementary Figure 4 ). To validate our observation, we measured p-Akt/Akt level and NF-kB DNA-binding activity in DU-145 cells stably overexpressing GFPC17orf37 (DU-GFP-C17), and as expected phosphorylation of Akt and NF-kB activity was significantly higher in C17orf37-overexpressed cells compared to vector control cells (DU-GFP) (Figure 6c ). These results demonstrate that C17orf37 mediates prostate cancer cell migration and invasion through NF-kB downstream target genes MMP-9, uPA and VEGF.
Discussion
C17orf37 is a novel gene located on human chromosome 17q12, in the 'hot spot locus of cancer' that contains multiple genes that have been shown to be involved in the progression of cancer. C17orf37 gene is 505 nucleotides from ERBB2 oncogene, which has been demonstrated as an important factor for development of hormone refractory prostate cancer (Berger et al., 2006) . Although C17orf37 overexpression in breast cancer has been linked with genomic amplification of Her-2/neu locus, recent report has confirmed overexpression of C17orf37 in Her-2/neu-negative breast cancer patients and breast tumor cell lines, suggesting independent transcriptional control mechanisms for C17orf37 (Evans et al., 2006) . In the present study, we show that C17orf37 expression is consistently higher in both androgen-dependent and -independent prostate cancer cell lines and clinical prostate cancer tissues examined, compared to either low or null expression in normal and BPH prostate cells and tissues (Figures 1 and 2) . In clinical prostate cancer specimens, higher Gleasonscored tumors showed increased C17orf37 expression compared to lower scores, suggesting C17orf37 expression may increase with grade and stage of cancer. However, the small number of established prostate cancer cell lines does not show significant changes in C17orf37. A larger study with more patient population will be necessary to establish C17orf37 as a biomarker for prostate cancer progression. Our data provide the .005 relative to mock treated (VEGF); **Po0.05 relative to mock (Lipofectamine) treated (MMP-9) and ## Po0.05 relative to mock treated (VEGF); statistical analysis included Student's t-test for calculating significant differences within groups.
Role of C17orf37 in prostate cancer S Dasgupta et al first evidence that C17orf37 expression positively correlates with the migratory and invasive potential of metastatic prostate cancer cells and thereby can be regarded as a potential biomarker for the disease progression. This is the first report delineating the role, functional significance and a proposed mechanism through which this novel gene C17orf37 governs prostate cancer progression.
C17orf37 gene encodes a protein (accession no. NP_115715) of 115 amino acids with a molecular weight of B12 kDa (Figure 1c; Supplementary Figure S2 ) that has no sequence similarity with any known genes or proteins (Evans et al., 2006; Kauraniemi and Kallioniemi, 2006) . By immunoconfocal microscopy, TIRFM and cellular fractionation studies we show that C17orf37 is predominantly a cytosolic protein, densely located in the cell membrane (Figure 3) . In migrating prostate cancer cell, C17orf37 protein primarily localizes to the leading edge of cell (Supplementary Figure 5) . Careful analysis of the C17orf37 protein sequence (Figure 1c ) revealed a 'CaaX' prenylation motif comprising of last four amino acids 'CVIL' at the C-terminal end. 'CaaX' group of proteins are either farnesylated or geranylgeranylated by enzymes farnesyltransferase and geranylgeranyl transferase type I (GGTase-I), respectively. If 'X' is leucine, protein is preferentially modified by GGTase-I enzyme (Fu and Casey, 1999) , suggesting C17orf37 translocation to the membrane may be mediated by GGTase-I. Pre-PS (prenylation prediction suite) predicted C17orf37 to be prenylated preferentially by the enzyme GGTase-I with a P-value ¼ 0.00049 (Maurer-Stroh and Eisenhaber, 2005) and this idea was also supported by a recent report (Evans et al., 2006) .
'CaaX'-type prenylated proteins are primarily located at the cytoplasmic face of cellular membranes and in cancer cells these proteins are found to have significant function in oncogenic transformation, cytoskeletal organization, cellular proliferation, migration, invasion and metastasis (Virtanen et al., 2002; Winter-Vann and Casey, 2005; Kelly et al., 2006) . By RNAi-mediated C17orf37 gene silencing and also by overexpressing C17orf37 in prostate cancer cells, we successfully established that C17orf37 regulates migration and invasion (Figure 4) . Even in patients with metastasis of breast cancer to liver and lungs, abundant expression of C17orf37 protein has been reported (Evans et al., 2006) . Migration and invasion of cancer cells are the hallmark of malignant neoplastic proliferation beyond the vascular boundaries facilitated by ECM cleavage by proteolytic enzymes. SiRNA mediated knockdown of C17orf37 in DU-145 cells, reduced mRNA and protein expression of important proteolytic enzymes MMP-9 and uPA, and potent angiogenic molecule VEGF (Figure 5 ), suggesting C17orf37 may act as an important upstream signaling molecule enhancing the transcription of these genes. uPA binding to its receptor uPA-R at the cell surface converts inactive plasminogen to active plasmin, and thereby cleaves ECM proteins inducing migration and invasion of malignant cells (Li and Cozzi, 2007) . MMP-9 specifically cleaves ECM proteins like gelatin, collagen I and IV, vitronectin and fibronectin resulting in metastatic dissemination of malignant cells (Price et al., 1997) . In prostate cancer development, angiogenic growth factor VEGF has key function in promoting tumor growth and metastatic progression of the disease. MMP-9, uPA and VEGF have been reported to be overexpressed in invasive prostate cancer (Wilson and Sinha, 1993) and are positively correlated with poor prognosis (Sheng, 2001) . We show here that by modulating C17orf37 expression in DU-145 metastatic prostate cancer cells, expression of these key molecules is significantly reduced, thereby inhibiting prostate cancer cell migration and invasion.
In invasive prostate cancer cells, increased expression of MMP-9, uPA and VEGF genes is regulated by transcriptional activation of NF-kB (Huang et al., 2001) . Activation of NF-kB is due to increased activity of upstream kinase IKK complex that greatly reduces the half-life of the inhibitory IkBa, thereby inducing nuclear localization of NF-kB (Suh and Rabson, 2004) . Knockdown of C17orf37 by gene-specific siRNA simultaneously reduced the DNA-binding activity of NF-kB, indicating C17orf37-mediated signaling may modulate MMP-9, uPA and VEGF genes through NF-kB pathway. This also justifies C17orf37 as an upstream signaling molecule of NF-kB. PI3K-Akt and mitogen-activated protein kinase are the two upstream signaling pathways that have been shown to be responsible for constitutive activation of IKK complex and NF-kB (Suh and Rabson, 2004) . In prostate cancer cells, PI3K-Akt works like a signaling hub mainly as a downstream effector of tyrosine kinase growth factor receptors. Modulation of C17orf37 dramatically altered the phosphorylation of Akt at Ser-473 (Figure 6 ), which indicates C17orf37 may act as an inducer of Akt phosphorylation. The ratio of phosphorylated ERK1/2 to the total ERK1/2 also decreased, albeit minimally, when compared to the control-siRNA-treated DU-145 cells. This decrease in ERK1/2 phosphorylation may be due to the reduced expression of uPA protein upon C17orf37 silencing. In prostate cancer cells, uPA binds to its cell-surface receptor uPA-R thereby activating ERK1/2 signaling (Jo et al., 2005) . Several studies have shown that knockdown of uPA abolishes the ERK1/2 phosphorylation (Aguirre Ghiso et al., 1999) , indicating decrease in ERK1/2 phosphorylation in C17orf37 knockdown cells may be due to the downstream target molecule uPA.
Thus, based on our data, we propose a mechanistic model for C17orf37-mediated signaling in prostate cancer invasion and signaling (Figure 6d ). In response to extracellular stimuli, growth receptors (tyrosine kinase) present on the prostate cancer cells cascade down the signal activating PI3K. This results in the activation of AKT that translocates to the membrane where it is phosphorylated at Ser-473 (Chan et al., 1999) . Prenylated protein C17orf37 also remains localized to the cytosolic face of the membrane (may be as an adapter protein) and in turn controls the downstream signaling of activated p-AKT. Whether this effect is direct or mediated through other adapter proteins that physically interact with C17orf37 on the membrane Figure 6 Knockdown of C17orf37 by siRNA reduces the nuclear factor-kB (NF-kB) DNA-binding activity by suppressing the AKT activation. (a) Electrophoretic mobility shift assay (EMSA) was carried out by incubating 5 mg of nuclear protein extracts from DU-145 cells treated with nontargeting siRNA (control siRNA) and 50, 75 and 100 nM siRNA specific to C17orf37. DU-145 cells treated with transfection media (mock) and in presence of competitive oligonucleotides to the probe (competitor) were used as controls. The nonsignificant band (NS) present in all the lanes did not have any effect even in the presence of competitor. (b) DU-145 prostate cancer cells were transiently transfected with nontargeting siRNA (control siRNA), and increasing concentration of C17orf37-specific siRNA at 50, 75 and 100 nM dose for 48 h. The expression of C17orf37, phospho-AKT (Ser 473), total AKT, phospho-ERK1/2 and total ERK1/2 was detected by western immunoblotting. Housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control to normalize the total AKT and ERK1/2 protein levels, and then used to determine the ratio of the phosphorylated/total AKT and ERK, respectively. needs further investigation. Activated AKT phosphorylates IKK complex that then results in the translocation of NF-kB to the nucleus by reducing the half-life of IkBa (Suh and Rabson, 2004) . In the nucleus NF-kB acts as transcription factor resulting in the enhanced expression of downstream target genes MMP-9, uPA and VEGF. These molecules are then secreted by prostate cancer cells and thereby increase the invasiveness of prostate cancer cells (Sliva, 2004) .
In summary, we find that C17orf37 is highly expressed in prostate cancer cells and tissues, compared to minimal expression in normal prostate cells. C17orf37 is predominantly expressed as a membrane-bound cytosolic protein and actively regulates prostate cancer cell migration and invasion by upregulating the expression of MMP-9, uPA and VEGF. In addition, downregulation of C17orf37 by specific siRNA reduced the DNA-binding activity of NF-kB, substantiating the fact that C17orf37 expression contributes to the development of invasive prostate cancer through NF-kBmediated downstream target genes. Interestingly, AKT activity was reduced due to C17orf37 gene silencing suggesting membrane-bound C17orf37 may be a potential regulator of AKT phosphorylation. We believe our results are the first report to deduce the functional importance of so-called 'hypothetical protein' C17orf37 that may be considered as a potential therapeutic target for cancer therapy.
Materials and methods
Cell lines and culture conditions Details describing cell culture and reagents are provided in the Supplementary information.
Cloning, expression and purification of recombinant C17orf37
Information about the plasmids constructed for the study and details about the protein expression and purification are given in Supplementary information. 
Cell fractionation and immunoblotting
Whole-cell protein extracts were prepared from prostate cell lines as described previously (Das et al., 2007) . Cytosolic and nuclear fractions of DU-145 and LNCaP cells were prepared using the NE-PER nuclear and cytoplasmic extraction kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Bacterial cell lysates were prepared using B-PER extraction kit (Pierce). Western immunoblot was performed using a 15% gel for C17orf37 protein analysis and 10% for other proteins, as described previously (Das et al., 2007) . List of antibodies purchased for the study is included in the Supplementary information.
Mass spectrometry and liquid chromatography-tandem mass spectrometry Mass spectrometry was performed using FTICR instrument (LTQ-FT; Thermo Fisher, San Jose, CA, USA) as described in Supplementary information.
Confocal microscopy, immunofluorescence and TIRFM DU-145 and LNCaP cells were grown on glass coverslips and treated with C17orf37 antibody (Zymed, Carlsbad, CA, USA). For confocal images, cells were visualized on a Zeiss LSM 410 confocal microscope and images were captured using LSM 4 software (Carl Zeiss Microimaging). For, TIRFM, cells were grown on coverslips and then fixed by 2% paraformaldehyde. Unpermeabilized cells were then washed with PBS and treated with C17orf37 or tubulin antibody (Calbiochem) followed by Alexa-568-conjugated secondary antibody. Coverslips were then mounted on specialized cover glass 1 (22 Â 50 mm size; Corning, Lowell, MA, USA). For TIRF images, cells were visualized on an Olympus IX71 microscope with commercial TIRF attachment as described previously (Burghardt et al., 2006) by Â 60 oil immersion objective.
Immunohistochemistry
Frozen prostate tumors from patients were provided by the UNMC/Eppley Cancer Center Tumor Bank (Omaha, NE, USA). Two anatomic pathologists independently graded the H&E-stained sections and Gleason scores for these tissues varied between 6 and 10. Immunohistochemistry was performed as described previously (Das et al., 2007) . C17orf37 antibody (Zymed) and rabbit IgG (Sigma, St Louis, MO, USA) were used for the immunohistochemistry study. Representative images of the clinical prostate sections were captured and analysed by the pathologist.
Cell migration assays
At 48-h after transfection with siRNA-C17orf37 or control siRNA, 1 Â 10 6 number of DU-145 cells were mixed with low melting agarose and growth medium to form a semisolid gel and migration assay was performed as described before (Das et al., 2007) . The cells were allowed to migrate out of the semisolid beads for 36 h and then visualized on an Olympus microscope (Carl Zeiss). Representative images of the cells were captured and the number of cells that migrate out of the beads was counted from three independent experiments. Fold change of migration was determined by a ratio of migrated cells in experimental group to the control group.
In vitro tumor invasion assay Tumor invasion assay was performed using BD Biocoat Tumor Invasion System (BD Biosciences, Bedford, MA, USA) according to the manufacturer's instructions. Details about the procedure are given in Supplementary information.
